...
首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial.
【24h】

Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial.

机译:在扩大的美国多中心旋律瓣试验中,经导管肺动脉瓣置入后的短期和中期结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Transcatheter pulmonary valve placement is an emerging therapy for pulmonary regurgitation and right ventricular outflow tract obstruction in selected patients. The Melody valve was recently approved in the United States for placement in dysfunctional right ventricular outflow tract conduits. METHODS AND RESULTS: From January 2007 to August 2009, 136 patients (median age, 19 years) underwent catheterization for intended Melody valve implantation at 5 centers. Implantation was attempted in 124 patients; in the other 12, transcatheter pulmonary valve placement was not attempted because of the risk of coronary artery compression (n=6) or other clinical or protocol contraindications. There was 1 death from intracranial hemorrhage after coronary artery dissection, and 1 valve was explanted after conduit rupture. The median peak right ventricular outflow tract gradient was 37 mm Hg before implantation and 12 mm Hg immediately after implantation. Before implantation, pulmonary regurgitation was moderate or severe in 92 patients (81% with data); no patient had more than mild pulmonary regurgitation early after implantation or during follow-up (>or=1 year in 65 patients). Freedom from diagnosis of stent fracture was 77.8+/-4.3% at 14 months. Freedom from Melody valve dysfunction or reintervention was 93.5+/-2.4% at 1 year. A higher right ventricular outflow tract gradient at discharge (P=0.003) and younger age (P=0.01) were associated with shorter freedom from dysfunction. CONCLUSIONS: In this updated report from the multicenter US Melody valve trial, we demonstrated an ongoing high rate of procedural success and encouraging short-term valve function. All reinterventions in this series were for right ventricular outflow tract obstruction, highlighting the importance of patient selection, adequate relief of obstruction, and measures to prevent and manage stent fracture. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00740870.
机译:背景:经导管置入肺动脉瓣是一种针对某些患者的肺返流和右室流出道阻塞的新兴疗法。 Melody瓣膜最近在美国获得批准,可用于功能障碍的右心室流出道导管中。方法和结果:从2007年1月至2009年8月,在5个中心进行了136例患者(中位年龄19岁)的预期的Melody瓣膜植入术。试图植入124例患者。在其他12例中,由于存在冠状动脉受压的风险(n = 6)或其他临床或方案禁忌症,因此未尝试置入经导管的肺动脉瓣。冠状动脉解剖后颅内出血死亡1例,导管破裂后移出1个瓣膜。植入前右心室流出道的中值峰值为37 mm Hg,植入后立即为12 mm Hg。植入前,92例患者的肺返流为中度或重度(有数据的81%);植入后或随访期间(65名患者中≥1年),没有患者有轻度的肺返流。在14个月时,诊断为支架断裂的自由度为77.8 +/- 4.3%。在1年时,摆脱旋律性瓣膜功能障碍或再次介入的自由度为93.5 +/- 2.4%。出院时右心室流出道梯度较高(P = 0.003)和年龄较小(P = 0.01)与功能障碍的缓解时间短有关。结论:在来自美国多中心Melody瓣膜试验的最新报告中,我们证明了程序成功率不断提高,并鼓励了短期瓣膜功能。该系列的所有再次干预均针对右心室流出道梗阻,突出了患者选择的重要性,充分缓解梗阻以及预防和管理支架骨折的措施的重要性。临床试验注册-URL:http://www.clinicaltrials.gov。唯一标识符:NCT00740870。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号